Home › Trial NCT04044560
Blinatumomab for MRD in Pre-B ALL Patients Following Stem Cell Transplant
- Trial IDNCT04044560
- StatusTerminated
- PhasePhase 2
- Study typeInterventional
- SponsorUniversity of British Columbia
- Enrollment8
- Start date2020-09-08
- ConditionsB-cell Adult Acute Lymphoblastic Leukemia · Stem Cell Leukemia · Minimal Residual Disease
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.